Cognition Therapeutics, Inc.

NASDAQ:CGTX

Biotechnology

Healthcare
$0.60 -0.70%

-$0.01 today

Market cap
$57.06M
Beta
1.75
P/E (TTM)
-6.4
EPS (TTM)
-$0.22
52W Low $0.25High $3.83

Volume 0.34M

Average 1.23M

CGTX Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Cognition Therapeutics, Inc.NASDAQ: CGTX

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI remains negative

Q1 FY2026 Accumulated OCI was $0, compared with $0 a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Accumulated OCI vs competitors

How CGTX compares with its peers on the latest reported figures

  • CGTX's Mar 2026 Accumulated OCI of $0 is the highest of the 8 companies compared; the peer median is $0.
  • Accumulated OCI amounts to 0.0% of total assets for CGTX, versus a peer median of 0.0%.
CGTX Competitors Peer median
Accumulated OCI for CGTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CGTXCognition Therapeutics, Inc.Mar 2026$0 ——0.0%
IRDOpus Genetics, Inc.Mar 2026$0 ——0.0%
SRZNSurrozen, Inc.Mar 2026$0 ——0.0%
GLSIGreenwich LifeSciences, Inc.Mar 2026$0 ——0.0%
SPROSpero Therapeutics, Inc.Mar 2026$0 ——0.0%
MCRBSeres Therapeutics, Inc.Mar 2026$0 ——0.0%
SEERSeer, Inc.Mar 2026-$64K -121.0%—0.0%
AGENAgenus Inc.Mar 2026-$437K +70.2%—0.2%
Peer median (excluding CGTX) $0-25.4%—0.0%

Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents54.72M41.56M29.92M25.01M36.81M
Short-term Investments00000
Net Receivables2.27M3.67M1.28M2.69M9.92M
Inventory00000
Other Current Assets11K03.02M01.26M
Total Current Assets58.99M47.65M34.22M29.56M47.99M
Property, Plant & Equipment (Net)145K1.05M941K679K399K
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets01.73M000
Total Non-current Assets145K2.78M941K679K399K
Total Assets59.14M50.43M35.16M30.23M48.39M
Account Payables4.17M3.22M3.7M1.98M1.12M
Short-term Debt0634K544K279K307K
Tax Payables00000
Deferred Revenue753K1.7M1.7M1.07M367K
Other Current Liabilities2.48M870K1.17M1.53M1.57M
Total Current Liabilities7.86M7.8M10.17M11.14M13.92M
Long-term Debt00000
Deferred Tax Liabilities0(695K)000
Deferred Revenue (Non-current)01.69M000
Other Non-current Liabilities0695K000
Total Non-current Liabilities02.38M520K342K195K
Total Liabilities7.86M10.18M10.69M11.48M14.12M
Common Stock22K29K32K60K90K
Retained Earnings(94M)(115.4M)(141.19M)(175.16M)(198.65M)
Accumulated OCI(198K)(199K)(195K)00
Other Stockholders Equity00000
Minority Interest00000
Total Equity51.27M40.25M24.47M18.75M34.27M
Total Debt01.48M1.24M814K638K
Net Debt(54.72M)(40.08M)(28.68M)(24.2M)(36.17M)

Cognition Therapeutics, Inc.

NASDAQ:CGTX

Intrinsic Alpha fair value

Locked

Current Price

$0.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.